CA2515663C - Chitosan-based transport system - Google Patents
Chitosan-based transport system Download PDFInfo
- Publication number
- CA2515663C CA2515663C CA 2515663 CA2515663A CA2515663C CA 2515663 C CA2515663 C CA 2515663C CA 2515663 CA2515663 CA 2515663 CA 2515663 A CA2515663 A CA 2515663A CA 2515663 C CA2515663 C CA 2515663C
- Authority
- CA
- Canada
- Prior art keywords
- transport system
- chitosan
- several
- chitin
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention relates to a chitosan-based transport system for overcoming the blood-brain barrier. This transport system can convey active agents or markers into the brain. The transport system contains at least one substance from the group of chitin, chitosan, chitosan oligosaccharides, and glucosamine or their derivatives, and optionally one or several active agents and/or one or several markers and/or one or several ligands.
Description
Chitosan-based transport system It is one of the great goals of pharmaceutical research to make the various barriers in the body selectively passable for specific substances. These include the intestine-blood barrier, the skin-blood barrier, the nasal mucosa-blood barrier, and the blood-brain barrier (BBB).
The blood-brain barrier (BBB) is one of the most problematic barriers as it has highly selective transport systems and as these cells are very tightly joined. The blood-brain barrier is formed by the endothelium of the capillary vessels. These endothelial cells adhere by tight junctions and prevent entry of polar substances exceeding a specific molecular weight into the brain. However, some nutrients (such as D-glucose) and hormones overcome the blood-brain barrier using selective transport systems.
Tight junctions (Latin: zonulae occludentes) are strip-shaped junctions of cell membranes that appear to be so tight under the electron microscope as if the membranes were fused. However, actual contact only occurs among the proteins embedded in the outer layer of the participating cell membranes. The protein involved is occludin, a transmembrane protein. The tight junctions occur over extremely short sections of a few nanometers that belong -as becomes visible in freeze breaks only - to a network of globular occludin molecules arranged in a chainlike order which "weld" the epithelial cells to each other.
A particular problem is the transport of hydrophilic substances through the BBB. Pharmaceutical researchers therefore are looking for ways to encapsule such hydrophilic substances in lipophilic particles or bind them to particles with substances that permit receptor-mediated transport across the BBB.
The blood-brain barrier (BBB) is one of the most problematic barriers as it has highly selective transport systems and as these cells are very tightly joined. The blood-brain barrier is formed by the endothelium of the capillary vessels. These endothelial cells adhere by tight junctions and prevent entry of polar substances exceeding a specific molecular weight into the brain. However, some nutrients (such as D-glucose) and hormones overcome the blood-brain barrier using selective transport systems.
Tight junctions (Latin: zonulae occludentes) are strip-shaped junctions of cell membranes that appear to be so tight under the electron microscope as if the membranes were fused. However, actual contact only occurs among the proteins embedded in the outer layer of the participating cell membranes. The protein involved is occludin, a transmembrane protein. The tight junctions occur over extremely short sections of a few nanometers that belong -as becomes visible in freeze breaks only - to a network of globular occludin molecules arranged in a chainlike order which "weld" the epithelial cells to each other.
A particular problem is the transport of hydrophilic substances through the BBB. Pharmaceutical researchers therefore are looking for ways to encapsule such hydrophilic substances in lipophilic particles or bind them to particles with substances that permit receptor-mediated transport across the BBB.
2 In recent years, they increasingly worked on transport systems consisting of nanoparticles. Nanoparticles mostly consist of polymers and are about 10 to 1000 nm in size [Kreuter, Journal of Anatomy 1996, 189, pp. 503-505]. Some researchers managed to produce efficient nanoparticles that ensure rapid transport of drug-charged particles across the BBB. Nanoparticles from polybutyl cyanoacrylate are able to transport drugs by encapsulating or binding them to the surface of the nanoparticles [Schroeder et al., Journal of Pharmaceutical Science 1998, 87, 11, pp.
1305-1307, Schroeder et al., Progress in Neuro-Psychopharmacology and Biological Psychiatry 1999, 23, pp.
941-949, Alyautdin et al., Pharmaceutical Research 1997, 14, 3, pp. 325-328, Ramge et al., European Journal of Neuroscience 2000, 12, pp. 1931-1940]. However, these nanoparticles cannot be transported across the BBB
directly, only by coating them with polysorbate 80 [Kreuter, Advanced Drug Delivery Reviews 2001, 47, pp. 65-81, Kreuter, Current Medicinal Chemistry-Central Nervous System Agents 2002, 2, pp. 241-249]. Nanoparticles consisting of polycyanoacrylate that were coated with polyethylene glycol could only overcome the BBB if, due to an infection of the brain, the BBB is defective and has become less permeable [Calvo et al., European Journal of Neuroscience 2002, 15, pp. 1317-1326]. Wang et al.
[Molecular Therapy 2001, 3, 5, pp. 658-664] found a cationic polymer (polyethylenimine) with which you can bypass the BBB and use an intramuscular injection in the tongue to introduce drugs into the brain using retrograde axonal transport. Rousselle et al. [Molecular Pharmacology 2000, 57, pp. 679-686] transported doxrubicin across the BBB using a peptide vector. The drug to be transported is covalently bound to D-penetrantin, a peptide, and synBl, which facilitates transport across the BBB without causing ejection by the P-glycoprotein. Other ways include
1305-1307, Schroeder et al., Progress in Neuro-Psychopharmacology and Biological Psychiatry 1999, 23, pp.
941-949, Alyautdin et al., Pharmaceutical Research 1997, 14, 3, pp. 325-328, Ramge et al., European Journal of Neuroscience 2000, 12, pp. 1931-1940]. However, these nanoparticles cannot be transported across the BBB
directly, only by coating them with polysorbate 80 [Kreuter, Advanced Drug Delivery Reviews 2001, 47, pp. 65-81, Kreuter, Current Medicinal Chemistry-Central Nervous System Agents 2002, 2, pp. 241-249]. Nanoparticles consisting of polycyanoacrylate that were coated with polyethylene glycol could only overcome the BBB if, due to an infection of the brain, the BBB is defective and has become less permeable [Calvo et al., European Journal of Neuroscience 2002, 15, pp. 1317-1326]. Wang et al.
[Molecular Therapy 2001, 3, 5, pp. 658-664] found a cationic polymer (polyethylenimine) with which you can bypass the BBB and use an intramuscular injection in the tongue to introduce drugs into the brain using retrograde axonal transport. Rousselle et al. [Molecular Pharmacology 2000, 57, pp. 679-686] transported doxrubicin across the BBB using a peptide vector. The drug to be transported is covalently bound to D-penetrantin, a peptide, and synBl, which facilitates transport across the BBB without causing ejection by the P-glycoprotein. Other ways include
3 transporting nanoparticles via the transferrin receptor by binding them to ligands [Li et al., Trends in Pharmacological Sciences 2002, 23, 5, pp. 206-209]. This system however has the setback that you can charge the particles with a small quantity of the substance to be transported only.
The previous results of nanoparticle research have shown that neither complicated manufacturing processes nor damage to the BBB is required to transport hydrophilic substances into the brain or that the coating substances are insufficiently decomposed and/or decomposed into harmful monomers.
Many prior art systems are based on coating materials that are composed of one or several cationic and/or anionic layers. Previous approaches were based on the assumption that the transport systems must be physically and chemically stable to protect their content (active agents) and take them to their destination. This is why most systems have very good mechanical properties and do not or do not readily dissolve in the bloodstream.
The use of monosaccharides for overcoming the blood-brain barrier was studied to some extent. US 6,294,520 B1 describes oral administration of monosaccharides and amino acids, among other purposes, for supporting the treatment of hair loss.
If an active ingredient has entered the bloodstream it can be metabolized by the liver, discharged by the kidney, or passed to the intestine by the gall bladder. This is why a high dose is often needed to get the required effective quantity to the affected tissues.
The previous results of nanoparticle research have shown that neither complicated manufacturing processes nor damage to the BBB is required to transport hydrophilic substances into the brain or that the coating substances are insufficiently decomposed and/or decomposed into harmful monomers.
Many prior art systems are based on coating materials that are composed of one or several cationic and/or anionic layers. Previous approaches were based on the assumption that the transport systems must be physically and chemically stable to protect their content (active agents) and take them to their destination. This is why most systems have very good mechanical properties and do not or do not readily dissolve in the bloodstream.
The use of monosaccharides for overcoming the blood-brain barrier was studied to some extent. US 6,294,520 B1 describes oral administration of monosaccharides and amino acids, among other purposes, for supporting the treatment of hair loss.
If an active ingredient has entered the bloodstream it can be metabolized by the liver, discharged by the kidney, or passed to the intestine by the gall bladder. This is why a high dose is often needed to get the required effective quantity to the affected tissues.
4 Chitosan has been known for some years now as a drug delivery system. Chitosan has some interesting properties and is studied in many areas of medicine and pharmaceutics. It is known that nanoparticles with chitosan coats or nanocapsules can transport pharmaceuticals into the body or overcome the skin-blood or intestine-blood barrier. These barriers are overcome relatively easily. However the blood-brain barrier (BBB) is one of the most problematic barriers to overcome as it has highly selective transport systems and as the cells are very tightly joined.
It is therefore the problem of the invention to provide a chitosan-based transport system for overcoming the blood-brain barrier. This transport system is to convey active agents or markers into the brain.
According to the invention, this problem is solved by a transport system containing at least one substance from the group of chitin, chitosan, chitosan oligosaccharides, and glucosamine or their derivatives, and optionally one or several active agents and/or one or several markers and/or one or several ligands.
Basic units of the transport system of the invention are building blocks of chitin, chitosan, chitosan oligosaccharides, and glucosamine or their derivatives. The term "chitosan oligosaccharide" includes both carbohydrates that consist of up to 10 monosaccharides and longer-chain polysaccharides. Chitosan is obtained from natural chitin by deacetylating the amide bond, the degree of deacetylation (DDA) being controllable. Chain length and molecular weight of chitosan oligosaccharides can also be accurately set during preparation. WO 03/029297 A2 describes the respective method.
Chitin, chitosan, or chitosan oligosaccharides can have different properties depending on chain length and degree of deacetylation. Both parameters, chain length and degree of deacetylation, can be set during preparation.
Chitosan oligosaccharides, chitosan, and chitin with molecular weights from 179 Da (glucosamine) to 400 kDa are used for the transport system of the invention. It is preferred that the chitosan oligosaccharides, chitosans, and chitins have molecular weights from 179 Da to 100 kDa. Particularly preferred are chitosan oligosaccharides, chitosans, and chitins with molecular weights from 179 Da to 1.8 kDa and chain lengths of 1 to 10 N-acetyl glucosamine or glucosamine rings.
Most preferred are chitosan oligosaccharides, chitosans, and chitins with molecular weights from 800 Da to 1.8 kDa and chain lengths of 5 to 10 N-acetyl glucosamine or glucosamine rings.
Chitin, the chitosans, and chitosan oligosaccarides have degrees of deacetylation from 0 to 1000.
The preferred degree of deacetylation (DDA) is in the range from 30 to 1000. Particularly preferred is a degree of deacetylation of 70 to 100%.
Active agents and/or markers and/or ligands can be bound in various ways to the basic units. A preferred way is binding via the NHZ group of the glucosamine rings. Fig. 1 shows diagrams of various options. Chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative are only referred to by the term "chitosan" in Fig. 1. These ligands are required to dock to the receptors.
The transport system according to the invention preferably is designed in such a way that the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative is bound to one or several active agents and/or one or several markers.
One or several ligands may be bound instead of active agents and/or markers, or, optionally, in addition to them.
In another preferred embodiment, the transport system is designed so that the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative is coated by one or several active agents. Likewise, one or several active agents can be coated by the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative. This substance may preferably be coated by another coating substance. Preferred coating substances are starch and/or alginate.
It is preferred that one or several markers and/or one or several ligands are bound to the coat of chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative or to the coat of active agent.
In this context, if another coating substance is present, it is preferred that one or several markers and/or one or several ligands are bound to the outer coat.
In another embodiment, the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative is present as a chain and is bound to one or several active agents and/or one or several markers.
It is preferred in this embodiment of the transport system according to the invention that chain-like chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative are bound to the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative.
It is particularly preferred in the two latter embodiments (chain) that one or several ligands are bound to the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative.
The bound ligands can connect to receptors on membranes. These substances preferably are substances from the group of transferrin, insulin, insulin-like growth factors, and polysorbate-80.
The transport system according to the invention preferably contains substances as active ingredient that develop an effect in the brain.
The transport system according to the invention is preferably solid, liquid, or semisolid.
It can be applied by oral, dermal, or parenteral administration (preferably by intravenous injection).
The transport system according to the invention overcomes body barriers (dermal, oral, etc.) and enters the vascular system.
The vascular system transports the particles, capsules, or molecules that partially re-arrange into specific cells or extracellular structures. Surprisingly, this also occurs across the blood-brain barrier.
Absorption in the brain could be proven by studies in mice that had the transport system according to the invention containing a fluorescent marker injected intravenously. Fig. 2 shows the fluorescence microscopic picture of a section through the brain from the area of the hippocampus. The hippocampus is the region in the brain that is responsible for short-term memory, forming associations, and recognition of situations and objects. Considerable changes of this region of the brain occur with diseases such as Alzheimer's disease.
You can see a clear accumulation of fluorescent particles in the pyramidal cell layers (Pz) of hippocampus subregions CA1, CA2, and CA3. (The bar at the bottom right in the figure represents 100 um.) Figure 3 shows a close-up shot of a neuronal cell comprising a high content of particles of the transport system according to the invention (black coloration) (The bar at the bottom right in the figure represents 100 um.).
It was found in studies that the composition can be reconfigured in the blood if, for example, long chitin or chitosan components disintegrate into short molecular blocks.
It was found surprisingly that the blood itself and primarily the erythrocytes in it can assume a filtering or sorting function causing the chitin or chitosan molecule chains to disintegrate into molecular blocks with preferably 4 to 10 chitin or chitosan rings (N-acetyl glucosamine or glucosamine rings). These form active agent transport mixtures that can be transported independently and are preferably transported by erythrocytes. Chitin or chitosan molecules having the same structures and molecular size as glucose or glucosamine transported by erythrocytes preferably bind to erythrocytes.
If such a rearrangement occurs in the blood, absorption preferably takes place by glucose transport points at the blood-brain barrier or blood-organ barrier. Depending on the organ and configuration, transport can also be achieved via tight junctions or endocytotic or receptor-mediated processes.
We found that the transport systems according to the invention have great affinity for specific cells. These are cells with a high metabolic activity (energy-consuming) cells that are characterized by considerable glucose consumption. In the brain, besides in microgliocytes, particles preferably accumulate in neuronal cells, more preferably in pyramidal neurons.
Absorption in the cells could be proven by studies in mice that had the transport system according to the invention containing a fluorescent marker injected intravenously. Figure 4 shows the fluorescence microscopic picture of a neuronal cell from the brain of a mouse. The cells stained with cell-specific and fluorescent markers (parvalbumin positive) appear dark gray. The transport system according to the invention is shown in black (the bar represents 50 um).
Figures 5 and 6 also show fluorescence microscopic pictures of tissue slices with neuronal cells. The cells are stained gray, the transport system appears in the form of black dots (the bar represents 50 Vim). It is clearly visible that the transport system (black) is located within the gray area (cell). The picture proves beyond doubt that the transport system is absorbed in the cells.
In addition to this accumulation in and on cells, accumulation at extracellular structures, preferably at structures rich in protein such as ~-amyloid plaques in the Alzheimer pathology.
Figure 7 shows a fluorescence microscopic picture of a tissue slice with a-amyloid plaque (2) where the transport system according to the invention (1) has accumulated (the bar represents 50um).
It can also be absorbed in inflammatory brain regions or in tumor tissue. Absorption is similar in other body tissues.
Cells with a high energy metabolism (such as inflammations, tumors) are addressed primarily again.
The mechanism of action of preferred absorption via the glucose transporter in addition to endocytotic and receptor-mediated processes also explains the special effect on active, inflammatory, and tumor cells. These cells have a particularly great growth-related energy demand.
Depending on the modification of the composition, the transport system and active agent are separated in the cell or passed on to other areas of the cell such as lipide-like structures for absorption in or accumulation at organellas such as mitochondria or the nucleus. If the composition or its chitin, chitosan, chitosan oligosaccharide, or glucosamine portion is absorbed in the nucleus, it accumulates at DNA
structures.
Accumulation sites in the cell could be proven by studies in mice that had the transport system according to the invention injected intravenously. Figure 8 shows a section of electron microscopic pictures of neuronal cell. The transport system has accumulated at specific cell structures, here the nuclear-investing membrane, and is indicated by a circle. The fluorescence microscopic picture in Figure 4 also clearly shows a concentration at specific sites in the cell.
Surprisingly, concentration (clustering) of various individual compositions may occur at extracellular structures.
If chitin, chitosan, chitosan oligosaccharide, or glucosamine (basic elements) and active agent are separated or if only the basic element is introduced into the body, it can cause the following effects:
- Accumulation at or depositing in the membranes of cells and/or organellas and the resulting influence on signal cascades.
- Change in absorption or discharge of substances of any kind such as growth factors, messenger substances, minerals, electrolytes, and others in or from the cell These effects can also occur without separation of the basic element from the active agent.
In addition to causing an effect in the cells, specific structures that are marked by the basic elements can be identified outside the cell and used for diagnostic purposes.
After the diagnosis or unfolding of the effect of the bound substances the transport system decomposes so that the bound substance remains in the cell or is transported as an unbound particle through the vascular system, decomposed, or discharged.
Chitin, chitosan, chitosan oligosaccharide, or glucosamine are decomposed without residue in the cell or in the body.
Thus the transport system according to the invention can, in a cell-specific manner, dock to, or penetrate into cells that have these features, even outside the brain.
Controlled accumulation of chitin, chitosan, chitosan oligosaccharide, or glucosamine and active agent particles makes it possible to introduce diagnostic or therapeutic agents and transport them to the focus of the disease or the action site. As the transport system according to the invention accumulates in the metabolically active cells whose metabolism is increased as compared to other cells low doses of diagnostic or therapeutic agents can be administered as these concentrate in the diseased tissues of the body.
In this respect, the transport system according to the invention can be used to produce an agent for diagnosing brain-specific diseases. The diagnosis of tumors and Alzheimer's disease is preferred. In addition, the transport system described can be used as a diagnostic or therapeutic agent with malignant brain tumors. For example, highly effective antitumor agents such as tamoxifen can be delivered to the site where the effect should develop.
If you link the transport system according to the invention to a radioactive substance, you can diagnose foci of disease (inflammations) or tumors in vivo even if they are present at a low concentration (metastases, tumors in their early stage).
In Alzheimer pathology, the invention enables you to bind a (3-amyloid-affine radioactive substance to the transport system of the invention for controlled identification of plaque foci and concentration of diagnostics there. If the marker does not concentrate, you can assume that there is no pathologic change.
To diagnose beta-amyloid deposits using positron emission tomography (PET) the chitosan transport system is labeled with C11 by methylating the chitosan. The target were specific activities of more than 2000 Ci/mmol.
The transport system according to the invention can be used for treating brain-specific diseases. The treatment of tumors and Alzheimer's disease is preferred.
Suitable active agents for treatment can be bound to the transport system according to the invention that concentrate at the diseased sites and penetrate into the cells. This allows for a relatively low dose in relation to the body, which reduces the side effects of the drugs.
Particularly preferred are active agents selected from the group of acetylcholine precursors, in particular, choline and lecithin, stimulants for acetylcholine release such as linopirdine, acetylcholine sterase inhibitors, in particular, tacrine, donepezile, rivastigmine, metrifonate, and galantamine, muscarine receptor agonists, in particular, xanomeline, milameline, AF102B, Lu25-109, SB202026, and talsaclidine, beta-sheet breakers, neutral endopeptidases such as neprilysine, painkillers, inflammation inhibitors such as propentofylline, ibuprofen, and indomethacin, antioxidants, neuroprotective agents, NMDA antagonists, and antirheumatics.
The nerve growth factor (NGF) is a particularly preferred active agent.
Preferred antioxidants are vitamins E, C; deprenyl (selegiline; MAO-B inhibitor), and gingko biloba.
Neuroprotective agents are preferably selected from the group of Q10, nicotin, cerebrolysin, piracetam, phosphatidyl serine, and acetyl-L-carnitine. A particularly preferred NMDA
antagonist is memantine.
Chitin or chitosan and chitosan oligosaccharide are decomposed without residue by the organism due to their glucose-like structure. We observed that chitosan was surprisingly resorbed from the urine in the kidney and returned to the body.
As the particles are decomposed without residue, no further load on the organism by harmful monomers occurs, and monomer that is formed is glucosamine.
It can be expected that the transport system of the invention, due to its capability to be conveyed via glucose transporters and/or the openings of tight junctions, will be able to overcome the blood-blood barrier between mother and fetus.
This capability can be utilized at the prenatal stage for diagnostic and therapeutic purposes.
The invention is explained in greater detail with reference to examples.
Exemplary embodiments Example 1 Intravenous administration of a mixture of chain-like chitosan with a molecular weight from 1.8 kDa to 300 kDa and a degree of deacetylation from 80 to 100% to which a peptide or polypeptide of maritime origin was bound for treating tumor diseases in the brain. Administration of 45 mg of active agent per day over a period of 90 days; the transport agent/active agent mixture is absorbed in normal saline and applied.
Example 2 Preparation of chitosan oligomer in pure form and with a low degree of deacetylation (DDA) < 80o and a molecular weight from 800 to 1600 Dalton for treating inflammatory diseases in the bloodstream (phlebitis), administration of <_ 0.2 mg/100 kg body weight.
Example 3 Preparation of chitosan oligomers with a high DDA > 80%
molecular weight 500 to 2500 Da and adding 0.2 parts of ibuprofen or indometacin and intravenous administration of 5 0,3 mg/100 kg body weight in 2 ml NaCl solution over 14 days to inhibit inflammations induced by local Alzheimer plaque Example 4 Preparation of chitosan oligomers with a high DDA and mixing with glucosamine solutions and gingko biloba extract at a ratio of 5 . 2 . 1 for oral mucosa penetration (gel film on palatum or lower lip area).
Example 5 Coupling of memantine to chitosan with a degree of deacetylation of 87% and a molecular weight of 1.8 kDa. The transport system is stabilized by another coating with chitosan (DDA 90%) with a molecular weight of 150 kDa. The preparation is administered orally once a day at a dose of mg of active ingredient in the first week that is increased at weekly increments of 2.5 mg to the maximum dose of mg/day.
Example 6 Coupling of donepezile, rivastigmine, or galantamine to chitosan transport system (DDA 85%,) so that the administered dose is 2 to 5 mg of active ingredient per day; chronic application over several weeks (40 weeks).
Figures 1 to 8 Figure 1: Various embodiments of the transport system according to the invention.
Figure 2: Fluorescence microscopic picture of a section through the brain of a mouse in the hippocampus region (the bar represents 100 um).
Figure 3: Close-up shot of a neuronal cell comprising a high content of particles of the transport system according to the invention (black coloration) (The bar at the bottom right in the figure represents 100 um.).
Figure 4: Fluorescence microscopic picture of a neuronal cell from the brain of a mouse. The stained cells are shown in dark gray. The transport system according to the invention is shown in black (the bar represents 50 um).
Figure 5: Fluorescence microscopic picture of a tissue slice with neuronal cells. The cells are stained gray, the transport system appears in the form of black dots (the bar represents
It is therefore the problem of the invention to provide a chitosan-based transport system for overcoming the blood-brain barrier. This transport system is to convey active agents or markers into the brain.
According to the invention, this problem is solved by a transport system containing at least one substance from the group of chitin, chitosan, chitosan oligosaccharides, and glucosamine or their derivatives, and optionally one or several active agents and/or one or several markers and/or one or several ligands.
Basic units of the transport system of the invention are building blocks of chitin, chitosan, chitosan oligosaccharides, and glucosamine or their derivatives. The term "chitosan oligosaccharide" includes both carbohydrates that consist of up to 10 monosaccharides and longer-chain polysaccharides. Chitosan is obtained from natural chitin by deacetylating the amide bond, the degree of deacetylation (DDA) being controllable. Chain length and molecular weight of chitosan oligosaccharides can also be accurately set during preparation. WO 03/029297 A2 describes the respective method.
Chitin, chitosan, or chitosan oligosaccharides can have different properties depending on chain length and degree of deacetylation. Both parameters, chain length and degree of deacetylation, can be set during preparation.
Chitosan oligosaccharides, chitosan, and chitin with molecular weights from 179 Da (glucosamine) to 400 kDa are used for the transport system of the invention. It is preferred that the chitosan oligosaccharides, chitosans, and chitins have molecular weights from 179 Da to 100 kDa. Particularly preferred are chitosan oligosaccharides, chitosans, and chitins with molecular weights from 179 Da to 1.8 kDa and chain lengths of 1 to 10 N-acetyl glucosamine or glucosamine rings.
Most preferred are chitosan oligosaccharides, chitosans, and chitins with molecular weights from 800 Da to 1.8 kDa and chain lengths of 5 to 10 N-acetyl glucosamine or glucosamine rings.
Chitin, the chitosans, and chitosan oligosaccarides have degrees of deacetylation from 0 to 1000.
The preferred degree of deacetylation (DDA) is in the range from 30 to 1000. Particularly preferred is a degree of deacetylation of 70 to 100%.
Active agents and/or markers and/or ligands can be bound in various ways to the basic units. A preferred way is binding via the NHZ group of the glucosamine rings. Fig. 1 shows diagrams of various options. Chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative are only referred to by the term "chitosan" in Fig. 1. These ligands are required to dock to the receptors.
The transport system according to the invention preferably is designed in such a way that the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative is bound to one or several active agents and/or one or several markers.
One or several ligands may be bound instead of active agents and/or markers, or, optionally, in addition to them.
In another preferred embodiment, the transport system is designed so that the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative is coated by one or several active agents. Likewise, one or several active agents can be coated by the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative. This substance may preferably be coated by another coating substance. Preferred coating substances are starch and/or alginate.
It is preferred that one or several markers and/or one or several ligands are bound to the coat of chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative or to the coat of active agent.
In this context, if another coating substance is present, it is preferred that one or several markers and/or one or several ligands are bound to the outer coat.
In another embodiment, the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative is present as a chain and is bound to one or several active agents and/or one or several markers.
It is preferred in this embodiment of the transport system according to the invention that chain-like chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative are bound to the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative.
It is particularly preferred in the two latter embodiments (chain) that one or several ligands are bound to the chitin, chitosan, chitosan oligosaccharide, glucosamine or their derivative.
The bound ligands can connect to receptors on membranes. These substances preferably are substances from the group of transferrin, insulin, insulin-like growth factors, and polysorbate-80.
The transport system according to the invention preferably contains substances as active ingredient that develop an effect in the brain.
The transport system according to the invention is preferably solid, liquid, or semisolid.
It can be applied by oral, dermal, or parenteral administration (preferably by intravenous injection).
The transport system according to the invention overcomes body barriers (dermal, oral, etc.) and enters the vascular system.
The vascular system transports the particles, capsules, or molecules that partially re-arrange into specific cells or extracellular structures. Surprisingly, this also occurs across the blood-brain barrier.
Absorption in the brain could be proven by studies in mice that had the transport system according to the invention containing a fluorescent marker injected intravenously. Fig. 2 shows the fluorescence microscopic picture of a section through the brain from the area of the hippocampus. The hippocampus is the region in the brain that is responsible for short-term memory, forming associations, and recognition of situations and objects. Considerable changes of this region of the brain occur with diseases such as Alzheimer's disease.
You can see a clear accumulation of fluorescent particles in the pyramidal cell layers (Pz) of hippocampus subregions CA1, CA2, and CA3. (The bar at the bottom right in the figure represents 100 um.) Figure 3 shows a close-up shot of a neuronal cell comprising a high content of particles of the transport system according to the invention (black coloration) (The bar at the bottom right in the figure represents 100 um.).
It was found in studies that the composition can be reconfigured in the blood if, for example, long chitin or chitosan components disintegrate into short molecular blocks.
It was found surprisingly that the blood itself and primarily the erythrocytes in it can assume a filtering or sorting function causing the chitin or chitosan molecule chains to disintegrate into molecular blocks with preferably 4 to 10 chitin or chitosan rings (N-acetyl glucosamine or glucosamine rings). These form active agent transport mixtures that can be transported independently and are preferably transported by erythrocytes. Chitin or chitosan molecules having the same structures and molecular size as glucose or glucosamine transported by erythrocytes preferably bind to erythrocytes.
If such a rearrangement occurs in the blood, absorption preferably takes place by glucose transport points at the blood-brain barrier or blood-organ barrier. Depending on the organ and configuration, transport can also be achieved via tight junctions or endocytotic or receptor-mediated processes.
We found that the transport systems according to the invention have great affinity for specific cells. These are cells with a high metabolic activity (energy-consuming) cells that are characterized by considerable glucose consumption. In the brain, besides in microgliocytes, particles preferably accumulate in neuronal cells, more preferably in pyramidal neurons.
Absorption in the cells could be proven by studies in mice that had the transport system according to the invention containing a fluorescent marker injected intravenously. Figure 4 shows the fluorescence microscopic picture of a neuronal cell from the brain of a mouse. The cells stained with cell-specific and fluorescent markers (parvalbumin positive) appear dark gray. The transport system according to the invention is shown in black (the bar represents 50 um).
Figures 5 and 6 also show fluorescence microscopic pictures of tissue slices with neuronal cells. The cells are stained gray, the transport system appears in the form of black dots (the bar represents 50 Vim). It is clearly visible that the transport system (black) is located within the gray area (cell). The picture proves beyond doubt that the transport system is absorbed in the cells.
In addition to this accumulation in and on cells, accumulation at extracellular structures, preferably at structures rich in protein such as ~-amyloid plaques in the Alzheimer pathology.
Figure 7 shows a fluorescence microscopic picture of a tissue slice with a-amyloid plaque (2) where the transport system according to the invention (1) has accumulated (the bar represents 50um).
It can also be absorbed in inflammatory brain regions or in tumor tissue. Absorption is similar in other body tissues.
Cells with a high energy metabolism (such as inflammations, tumors) are addressed primarily again.
The mechanism of action of preferred absorption via the glucose transporter in addition to endocytotic and receptor-mediated processes also explains the special effect on active, inflammatory, and tumor cells. These cells have a particularly great growth-related energy demand.
Depending on the modification of the composition, the transport system and active agent are separated in the cell or passed on to other areas of the cell such as lipide-like structures for absorption in or accumulation at organellas such as mitochondria or the nucleus. If the composition or its chitin, chitosan, chitosan oligosaccharide, or glucosamine portion is absorbed in the nucleus, it accumulates at DNA
structures.
Accumulation sites in the cell could be proven by studies in mice that had the transport system according to the invention injected intravenously. Figure 8 shows a section of electron microscopic pictures of neuronal cell. The transport system has accumulated at specific cell structures, here the nuclear-investing membrane, and is indicated by a circle. The fluorescence microscopic picture in Figure 4 also clearly shows a concentration at specific sites in the cell.
Surprisingly, concentration (clustering) of various individual compositions may occur at extracellular structures.
If chitin, chitosan, chitosan oligosaccharide, or glucosamine (basic elements) and active agent are separated or if only the basic element is introduced into the body, it can cause the following effects:
- Accumulation at or depositing in the membranes of cells and/or organellas and the resulting influence on signal cascades.
- Change in absorption or discharge of substances of any kind such as growth factors, messenger substances, minerals, electrolytes, and others in or from the cell These effects can also occur without separation of the basic element from the active agent.
In addition to causing an effect in the cells, specific structures that are marked by the basic elements can be identified outside the cell and used for diagnostic purposes.
After the diagnosis or unfolding of the effect of the bound substances the transport system decomposes so that the bound substance remains in the cell or is transported as an unbound particle through the vascular system, decomposed, or discharged.
Chitin, chitosan, chitosan oligosaccharide, or glucosamine are decomposed without residue in the cell or in the body.
Thus the transport system according to the invention can, in a cell-specific manner, dock to, or penetrate into cells that have these features, even outside the brain.
Controlled accumulation of chitin, chitosan, chitosan oligosaccharide, or glucosamine and active agent particles makes it possible to introduce diagnostic or therapeutic agents and transport them to the focus of the disease or the action site. As the transport system according to the invention accumulates in the metabolically active cells whose metabolism is increased as compared to other cells low doses of diagnostic or therapeutic agents can be administered as these concentrate in the diseased tissues of the body.
In this respect, the transport system according to the invention can be used to produce an agent for diagnosing brain-specific diseases. The diagnosis of tumors and Alzheimer's disease is preferred. In addition, the transport system described can be used as a diagnostic or therapeutic agent with malignant brain tumors. For example, highly effective antitumor agents such as tamoxifen can be delivered to the site where the effect should develop.
If you link the transport system according to the invention to a radioactive substance, you can diagnose foci of disease (inflammations) or tumors in vivo even if they are present at a low concentration (metastases, tumors in their early stage).
In Alzheimer pathology, the invention enables you to bind a (3-amyloid-affine radioactive substance to the transport system of the invention for controlled identification of plaque foci and concentration of diagnostics there. If the marker does not concentrate, you can assume that there is no pathologic change.
To diagnose beta-amyloid deposits using positron emission tomography (PET) the chitosan transport system is labeled with C11 by methylating the chitosan. The target were specific activities of more than 2000 Ci/mmol.
The transport system according to the invention can be used for treating brain-specific diseases. The treatment of tumors and Alzheimer's disease is preferred.
Suitable active agents for treatment can be bound to the transport system according to the invention that concentrate at the diseased sites and penetrate into the cells. This allows for a relatively low dose in relation to the body, which reduces the side effects of the drugs.
Particularly preferred are active agents selected from the group of acetylcholine precursors, in particular, choline and lecithin, stimulants for acetylcholine release such as linopirdine, acetylcholine sterase inhibitors, in particular, tacrine, donepezile, rivastigmine, metrifonate, and galantamine, muscarine receptor agonists, in particular, xanomeline, milameline, AF102B, Lu25-109, SB202026, and talsaclidine, beta-sheet breakers, neutral endopeptidases such as neprilysine, painkillers, inflammation inhibitors such as propentofylline, ibuprofen, and indomethacin, antioxidants, neuroprotective agents, NMDA antagonists, and antirheumatics.
The nerve growth factor (NGF) is a particularly preferred active agent.
Preferred antioxidants are vitamins E, C; deprenyl (selegiline; MAO-B inhibitor), and gingko biloba.
Neuroprotective agents are preferably selected from the group of Q10, nicotin, cerebrolysin, piracetam, phosphatidyl serine, and acetyl-L-carnitine. A particularly preferred NMDA
antagonist is memantine.
Chitin or chitosan and chitosan oligosaccharide are decomposed without residue by the organism due to their glucose-like structure. We observed that chitosan was surprisingly resorbed from the urine in the kidney and returned to the body.
As the particles are decomposed without residue, no further load on the organism by harmful monomers occurs, and monomer that is formed is glucosamine.
It can be expected that the transport system of the invention, due to its capability to be conveyed via glucose transporters and/or the openings of tight junctions, will be able to overcome the blood-blood barrier between mother and fetus.
This capability can be utilized at the prenatal stage for diagnostic and therapeutic purposes.
The invention is explained in greater detail with reference to examples.
Exemplary embodiments Example 1 Intravenous administration of a mixture of chain-like chitosan with a molecular weight from 1.8 kDa to 300 kDa and a degree of deacetylation from 80 to 100% to which a peptide or polypeptide of maritime origin was bound for treating tumor diseases in the brain. Administration of 45 mg of active agent per day over a period of 90 days; the transport agent/active agent mixture is absorbed in normal saline and applied.
Example 2 Preparation of chitosan oligomer in pure form and with a low degree of deacetylation (DDA) < 80o and a molecular weight from 800 to 1600 Dalton for treating inflammatory diseases in the bloodstream (phlebitis), administration of <_ 0.2 mg/100 kg body weight.
Example 3 Preparation of chitosan oligomers with a high DDA > 80%
molecular weight 500 to 2500 Da and adding 0.2 parts of ibuprofen or indometacin and intravenous administration of 5 0,3 mg/100 kg body weight in 2 ml NaCl solution over 14 days to inhibit inflammations induced by local Alzheimer plaque Example 4 Preparation of chitosan oligomers with a high DDA and mixing with glucosamine solutions and gingko biloba extract at a ratio of 5 . 2 . 1 for oral mucosa penetration (gel film on palatum or lower lip area).
Example 5 Coupling of memantine to chitosan with a degree of deacetylation of 87% and a molecular weight of 1.8 kDa. The transport system is stabilized by another coating with chitosan (DDA 90%) with a molecular weight of 150 kDa. The preparation is administered orally once a day at a dose of mg of active ingredient in the first week that is increased at weekly increments of 2.5 mg to the maximum dose of mg/day.
Example 6 Coupling of donepezile, rivastigmine, or galantamine to chitosan transport system (DDA 85%,) so that the administered dose is 2 to 5 mg of active ingredient per day; chronic application over several weeks (40 weeks).
Figures 1 to 8 Figure 1: Various embodiments of the transport system according to the invention.
Figure 2: Fluorescence microscopic picture of a section through the brain of a mouse in the hippocampus region (the bar represents 100 um).
Figure 3: Close-up shot of a neuronal cell comprising a high content of particles of the transport system according to the invention (black coloration) (The bar at the bottom right in the figure represents 100 um.).
Figure 4: Fluorescence microscopic picture of a neuronal cell from the brain of a mouse. The stained cells are shown in dark gray. The transport system according to the invention is shown in black (the bar represents 50 um).
Figure 5: Fluorescence microscopic picture of a tissue slice with neuronal cells. The cells are stained gray, the transport system appears in the form of black dots (the bar represents
5 0 um ) .
Figure 6: Fluorescence microscopic picture of a tissue slice with neuronal cells. The cells are stained gray, the transport system appears in the form of black dots (the bar represents 50 um) .
Figure 7: Fluorescence microscopic picture of a tissue slice with (3-amyloid plaque (2) where the transport system according to the invention (1) has accumulated (the bar represents 50um) .
Figure 8: Section of a electron microscopic image of a neuronal cell. The transport system has accumulated at the nuclear-investing membrane and is indicated by a circle.
Figure 6: Fluorescence microscopic picture of a tissue slice with neuronal cells. The cells are stained gray, the transport system appears in the form of black dots (the bar represents 50 um) .
Figure 7: Fluorescence microscopic picture of a tissue slice with (3-amyloid plaque (2) where the transport system according to the invention (1) has accumulated (the bar represents 50um) .
Figure 8: Section of a electron microscopic image of a neuronal cell. The transport system has accumulated at the nuclear-investing membrane and is indicated by a circle.
Claims (27)
1. Transport system for overcoming the blood-brain barrier containing at least one substance from the group of chitin, chitosan, chitosan oligosaccharides, and their derivatives, and optionally one or several active agents and/or one or several markers and/or one or several ligands.
2. The transport system according to claim 1 wherein the chitosan oligosaccharides, chitosans, and chitins have molecular weights from more than 179 Da to 400 kDa.
3. The transport system according to either claims 1 or 2 wherein the chitosan oligosaccharides, chitosans, and chitins have molecular weights from more than 179 Da to 100 kDa.
4. The transport system according to any one of claims 1 to 3 wherein the chitosan oligosaccharides, chitosans, and chitins have molecular weights from more than 179 Da to 1.8 kDa and chain lengths of 2 to 10 N-acetyl glucosamine or glucosamine rings.
5. The transport system according to any one of claims 1 to 4 wherein the chitosan oligosaccharides, chitosans, and chitins have molecular weights from 800 Da to 1.8 kDa and chain lengths of 5 to 10 N-acetyl glucosamine or glucosamine rings.
6. The transport system according to any one of claims 1 to 5 wherein the chitins, chitosans and chitosan oligosaccharides have a degree of deacetylation of 30 to 100%.
7. The transport system according to any one of claims 1 to 6 wherein the chitins, chitosans and chitosan oligosaccharides have a degree of deacetylation of 70 to 100%.
8. The transport system according to any one of claims 1 to 7 wherein the chitin, chitosan, chitosan oligosaccharide or their derivative is bound to one or several active agents and/or one or several markers.
9. The transport system according to any one of claims 1 to 8 wherein the chitin, chitosan, chitosan oligosaccharide or their derivative is bound to one or several ligands.
10. The transport system according to any one of claims 1 to 9 wherein the chitin, chitosan, chitosan oligosaccharide or their derivative is coated by a coat comprising one or several active agents.
11. The transport system according to any one of claims 1 to 9 wherein one or several active agents are coated by a coat comprising the chitin, chitosan, chitosan oligosaccharide or their derivative.
12. The transport system according to claim 11 wherein the transport system is coated by an outer coat comprising another coating substance.
13. The transport system according to claim 12 wherein the coating substance is starch and/or alginate.
14. The transport system according to claims 10 or 11 wherein one or several markers and/or one or several ligands are bound to the coat.
15. The transport system according to claim 12 wherein one or several markers and/or one or several ligands are bound to the outer coat.
16. The transport system according to any one of claims 1 to 7 wherein the chitin, chitosan, chitosan oligosaccharide or their derivative is present in form of a chain and bound to the one or several active agents and/or the one or several markers.
17. The transport system according to claim 16 wherein chain-like chitin, chitosan, chitosan oligosaccharide or their derivative are bound to the chitin, chitosan, chitosan oligosaccharide or their derivative.
18. The transport system according to either claims 16 or 17 wherein one or several ligands are bound to the chitin, chitosan, chitosan oligosaccharide or their derivative.
19. The transport system according to any one of claims 1 to 18 wherein the active agents contained are substances that develop an effect in the brain.
20. The transport system according to claim 19 wherein substances from the group of acetylcholine precursors, stimulants for acetylcholine release, acetylcholine esterase inhibitors, muscarine receptor agonists, beta-sheet breakers, neutral endopeptidases, painkillers, inflammation inhibitors, antioxidants, neuroprotective agents, NMDA antagonists, antirheumatics, and nerve growth factors are contained as active agents.
21. The transport system according to any one of claims 1 to 20 wherein substances from the group of transferrin, insulin, insulin-like growth factors, and polysorbate 80 are contained as ligands.
22. Use of the transport system according to any one of claims 1 to 21 for treating brain-specific diseases.
23. Use of the transport system according to claim 22 for treating tumors.
24. Use of the transport system according to claim 22 for treating Alzheimer's disease.
25. Use of the transport system according to any one of claims 1 to 21 for preparing a diagnostic agent for brain-specific diseases.
26. Use of the transport system according to claim 25 for tumor diagnosis.
27. Use of the transport system according to claim 25 for diagnosing Alzheimer's disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004040243A DE102004040243A1 (en) | 2003-08-22 | 2004-08-13 | Transport system for overcoming the blood-brain barrier, useful for the treatment and diagnosis of brain-specific diseases, comprises chitin, chitosan, chitosan oligosaccharides or glucosamine |
| DE102004040243.4 | 2004-08-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2515663A1 CA2515663A1 (en) | 2006-02-13 |
| CA2515663C true CA2515663C (en) | 2011-10-18 |
Family
ID=35852089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2515663 Expired - Fee Related CA2515663C (en) | 2004-08-13 | 2005-08-11 | Chitosan-based transport system |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2515663C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10973774B2 (en) * | 2016-04-26 | 2021-04-13 | Viaqua Therapeutics Ltd. | Compositions and methods for treating viral infections in shrimps |
-
2005
- 2005-08-11 CA CA 2515663 patent/CA2515663C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2515663A1 (en) | 2006-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060051423A1 (en) | Chitosan-based transport system | |
| Liu et al. | Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: opportunities and emerging strategies | |
| US20210338593A1 (en) | Multistage delivery of active agents | |
| Lin et al. | GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy | |
| Li et al. | Dual-function nanostructured lipid carriers to deliver IR780 for breast cancer treatment: Anti-metastatic and photothermal anti-tumor therapy | |
| Zhang et al. | Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration | |
| EP1423095B1 (en) | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy | |
| Song et al. | Nanolayer encapsulation of insulin-chitosan complexes improves efficiency of oral insulin delivery | |
| Wilson et al. | Nanoparticles based on albumin: preparation, characterization and the use for 5-flurouracil delivery | |
| Allawadhi et al. | Biomedical applications of polysaccharide nanoparticles for chronic inflammatory disorders: Focus on rheumatoid arthritis, diabetes and organ fibrosis | |
| Raval et al. | Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities | |
| Fang et al. | SN38-loaded< 100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study | |
| Dangi et al. | Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles | |
| CN103370059A (en) | A drug delivery device | |
| Patel et al. | Development and characterization of glutathione-conjugated albumin nanoparticles for improved brain delivery of hydrophilic fluorescent marker | |
| CN101325947A (en) | Liposome combination | |
| Su et al. | Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy | |
| Li et al. | Gemcitabine-loaded albumin nanospheres (GEM-ANPs) inhibit PANC-1 cells in vitro and in vivo | |
| Yang et al. | Doxorubicin and edelfosine combo-loaded lipid–polymer hybrid nanoparticles for synergistic anticancer effect against drug-resistant osteosarcoma | |
| Demirtürk et al. | Nanocarriers targeting the diseases of the pancreas | |
| Xu et al. | Colon-targeting Angelica sinensis polysaccharide nanoparticles with dual responsiveness for alleviation of ulcerative colitis | |
| Tariq et al. | Nanogel-Based transdermal drug delivery system: A therapeutic strategy with under discussed potential | |
| Ismail et al. | Stimuli-responsive and biomimetic delivery systems for sepsis and related complications | |
| Carissimi et al. | Nanoparticles as drug delivery systems | |
| CA2515663C (en) | Chitosan-based transport system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150811 |